Position in GALT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
2 quarters on record
Derivatives in GALT
reported options exposure · as of Jun 30, 2026CallValue
$3,712,000
CallShares
800,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026GREAT POINT PARTNERS LLC holds $397,271,949 across 33 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VOR |
Vor Biopharma Inc.
|
1,700,000 | $31,297,000 | |
| 2 | ABVX |
Abivax S.A.
|
204,314 | $27,226,883 | |
| 3 | VERA |
Vera Therapeutics, Inc.
|
600,836 | $25,781,872 | |
| 4 | ZURA |
Zura Bio Ltd
|
4,215,930 | $24,873,987 | |
| 5 | ALMS |
Alumis Inc.
|
856,061 | $24,089,556 | |
| 6 | SLGL |
Sol-Gel Technologies Ltd.
|
274,363 | $20,341,272 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
425,000 | $19,992,000 | |
| 8 | ANNX |
Annexon, Inc.
|
3,500,000 | $19,985,000 |
All Filings in GALT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,712,000 | 800,000 | Call | Defined | 2026-08-14 | |
| 2026-03-31 | $2,232,000 | 800,000 | Call | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||